Table 1. Rapid diagnostic test results and prescription of anti-influenza agents in Izu-Oshima.
| Influenza season and influenza virus type* | Prescriptions written at clinics, no. (%) |
Total | ||||
|---|---|---|---|---|---|---|
| Oseltamivir† | Zanamivir‡ | Peramivir§ | Laninamivir¶# | None | ||
| 2008–09 | ||||||
| A | 193 (53.5) § | 45 (12.5)§ | 0 | 0 | 124 (34.3) | 361 |
| B | 39 (32.5) | 29 (24.2) | 0 | 0 | 52 (43.3) | 120 |
| A + B | 2 (3.3) | 0 | 0 | 0 | 4 (66.7) | 6 |
| Negative | 32 (5.5) | 10 (1.7) | 0 | 0 | 537 (92.8) | 579 |
| 2009–10 | ||||||
| A | 219 (48.5) | 209 (46.2) | 0 | 0 | 24 (5.3) | 452 |
| Negative | 42 (4.7) | 33 (3.7) | 0 | 0 | 828 (91.7) | 903 |
| 2010–11 | ||||||
| A | 147 (66.2) | 52 (23.4) | 3 (1.4) | 0 | 20 (9.0) | 222 |
| B | 60 (38.0) | 82 (51.9) | 1 (0.6) | 1 (0.6) | 14 (8.9) | 158 |
| Negative | 44 (7.2) | 18 (3.0) | 0 | 0 | 548 (89.8) | 610 |
*Influenza virus type determined by rapid diagnostic test. †Tamiflu, Chugai Pharmaceutical Co., Tokyo, Japan. ‡Relenza, GlaxoSmithKline, Research Triangle Park, NC, USA. §Rapiacta, BioCryst Pharmaceuticals Inc., Durham, NC, USA; marketed since January 27, 2010. ¶Inavir, Daiichi Sankyo Co., Ltd., Tokyo, Japan; marketed since October 19, 2010. #IIncludes 1 case for which Tamiflu and Relenza were prescribed.